Author: Buschbeck Marcus
Publisher: Adis International
ISSN: 1174-5886
Source: Drugs in R&D, Vol.7, Iss.2, 2006-01, pp. : 73-86
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Inhibition of oncogenic protein kinases by small compound inhibitors has proven to be a valuable strategy for the directed and target-specific treatment of an ever-increasing number of cancer types. These include the treatment of chronic myeloid leukemia with the Bcr-Abl inhibitor imatinib and non-small-cell lung cancer with the epidermal growth factor inhibitors erlotinib and gefitinib. Unfortunately, initially successful therapy is often hampered by relatively rapid onset of resistance to the drug and subsequent relapse, particularly in patients with advanced disease. In the majority of cases this is caused by expansion of clones containing mutated forms of the targeted kinases, which confer insensitivity to the drug of the cancer cell. In addition, multiple factors including pharmacokinetic issues such as suboptimal drug delivery further contribute to resistance formation. Loss of target dependence due to the activation of parallel signaling pathways has also been reported as cause for acquired drug insensitivity. Here, we discuss currently applied as well as potential future strategies that can be applied to overcome and avoid resistance to drug therapy.
Related content
Protein tyrosine kinase inhibitors in cancer treatment
By Traxler P.M.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. :
Development of RET Kinase Inhibitors for Targeted Cancer Therapy
Current Medicinal Chemistry, Vol. 18, Iss. 2, 2011-01 ,pp. :
Strategies for the Design of Selective Protein Kinase Inhibitors
Mini Reviews in Medicinal Chemistry, Vol. 8, Iss. 12, 2008-10 ,pp. :